{
    "name": "pafolacianine",
    "comment": "Rx",
    "other_names": [
        "Cytalux"
    ],
    "classes": [
        "Diagnostic Imaging Agents"
    ],
    "source": "https://reference.medscape.com/drug/cytalux-pafolacianine-4000180",
    "pregnancy": {
        "common": [
            "Based on its mechanism of action, fetal harm may occur when administer to pregnant females",
            "No human data are available to evaluate for drug-associated risk of major birth defects, miscarriage, or other adverse maternal fetal outcomes",
            "Verify pregnancy status of females of reproductive potential before administration"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "There are no data on the presence of pafolacianine in either human or animal milk, effects on breastfed infants, or effects on milk production"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Infusion-related reactions consisting of nausea, vomiting, abdominal pain, flushing, dyspepsia, hypersensitivity, elevated blood pressure, and chest discomfort reported; reactions typically occurred within 15 min after starting infusion",
                "Errors may occur during intraoperative fluorescence imaging to detect ovarian cancer and lesions in the lung, including false negatives and false positives; nonfluorescing tissue in the surgical field does not rule out the presence of ovarian or lung cancer; fluorescence may be seen in normal tissues including bowel, kidneys, lymph nodes, and lungs as well as in inflamed tissues",
                "Based on its mechanism of action, fetal harm may occur when administered to pregnant females",
                "Use only D5W to dilute drug; using an incorrect diluent to prepare infusion solution can cause aggregation of pafolacianine; aggregation may induce infusion reactions, such as nausea, vomiting, abdominal pain, or rash"
            ],
            "specific": [
                {
                    "type": "Drug interactions overview",
                    "description": [
                        "Folate, folic acid, or folate-containing supplements",
                        "Avoid use within 48 hr before administration",
                        "Use of folate, folic acid, or folate-containing supplements may reduce binding of pafolacianine to folate receptors overexpressed on ovarian cancer cells and could reduce the detection of malignant lesion"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "folic acid",
            "description": {
                "common": "folic acid decreases effects of pafolacianine by receptor binding competition. Avoid or Use Alternate Drug. Avoid coadministration with folic acid or folic acid-containing supplements for 48 hr before administering pafolacianine. Use of folate, folic acid, or folate-containing supplements may reduce binding of pafolacianine to folate receptors overexpressed on ovarian cancer cells and could reduce the detection of malignant lesions with. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "iron/folic acid/vitamin/mineral",
            "description": {
                "common": "iron/folic acid/vitamin/mineral decreases effects of pafolacianine by receptor binding competition. Avoid or Use Alternate Drug. Avoid coadministration with folic acid or folic acid-containing supplements for 48 hr before administering pafolacianine. Use of folate, folic acid, or folate-containing supplements may reduce binding of pafolacianine to folate receptors overexpressed on ovarian cancer cells and could reduce the detection of malignant lesions with. ."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Nausea",
            "percent": "15"
        },
        {
            "name": "Vomiting",
            "percent": "5.8"
        },
        {
            "name": "Abdominal pain",
            "percent": "2.7"
        },
        {
            "name": "Flushing",
            "percent": "1.7"
        },
        {
            "name": "Dyspepsia",
            "percent": "1"
        },
        {
            "name": "Chest discomfort",
            "percent": "1"
        },
        {
            "name": "Pruritus",
            "percent": "1"
        },
        {
            "name": "Hypersensitivity",
            "percent": "1"
        }
    ]
}